Randomized trial reveals potent anticancer effects of Schiff bases in human cancer cells, indicating a promising direction for drug development.
Key Points
The study aims to investigate the synthesis, characterization, and anticancer activity of specific Schiff bases derived from sulfadiazine and salicylaldehyde.
Synthesis and characterization of Schiff bases SB1 and SB2 using FTIR and NMR techniques.
Cytotoxicity evaluation against human cancer cells (HCT116, MCF-7, A549, HepG2, T24) using MTT assay.
Molecular docking studies to predict interactions with target proteins involved in cancer progression.
SB1 showed the strongest antiproliferative effect on MCF-7 (IC50 = 66.27 ± 1.14 µg/mL).
SB2 exhibited the highest activity against MCF-7 (IC50 = 59.61 ± 1.59 µg/mL) and notable effects on other cancer cells.
Both compounds induced oxidative stress and apoptosis in cancer cells, with strong binding affinities noted in molecular docking studies.